Emerging therapies for breast cancer

被引：54

作者：

Hu, Xichun ^{[1
,2
]}

Huang, Wei ^{[3
]}

Fan, Minhao ^{[4
]}

机构：

[1] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China

[3] Roche Prod Dev Asia Pacific, 5F,Tower C,Parkview Green 9,Dongdaqiao Rd, Beijing 100020, Peoples R China

[4] Hutchison MediPharma Ltd, Bldg 4 917 Halei Rd Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷

关键词：

Breast cancer; CDK4/6; inhibitors; SERD; PD1 and PD-L1 antibodies; PARP inhibitors; Fulvestrant; ADC; Nab-paclitaxel; TUMOR-INFILTRATING LYMPHOCYTES; KINASE; 4/6; INHIBITOR; EPITHELIAL-MESENCHYMAL TRANSITION; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; ESTROGEN-RECEPTOR-ALPHA; SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; FULVESTRANT; 500; MG; DNA-REPAIR DEFECT;

D O I：

10.1186/s13045-017-0466-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.

引用

页数：17

共 177 条

[1] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC). [J].

Adams, Sylvia ;

Diamond, Jennifer Robinson ;

Hamilton, Erika Paige ;

Pohlmann, Paula Raffin ;

Tolaney, Sara M. ;

Molinero, Luciana ;

He, Xian ;

Waterkamp, Daniel ;

Funke, Roel Peter ;

Powderly, John D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[2] Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro [J].

Agoulnik, Sergei I. ;

Kawano, Satoshi ;

Taylor, Noel ;

Oestreicher, Judith ;

Matsui, Junji ;

Chow, Jesse ;

Oda, Yoshiya ;

Funahashi, Yasuhiro .

VASCULAR CELL, 2014, 6

[3] PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes [J].

Ali, H. R. ;

Glont, S. -E. ;

Blows, F. M. ;

Provenzano, E. ;

Dawson, S. -J. ;

Liu, B. ;

Hiller, L. ;

Dunn, J. ;

Poole, C. J. ;

Bowden, S. ;

Earl, H. M. ;

Pharoah, P. D. P. ;

Caldas, C. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1488-1493

[4] The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma [J].

Altenburg, Jeffrey D. ;

Farag, Sherif S. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (02) :261-271

[5] A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells [J].

Anders, Lars ;

Ke, Nan ;

Hydbring, Per ;

Choi, Yoon J. ;

Widlund, Hans R. ;

Chick, Joel M. ;

Zhai, Huili ;

Vidal, Marc ;

Gygi, Stephen P. ;

Braun, Pascal ;

Sicinski, Piotr .

CANCER CELL, 2011, 20 (05) :620-634

[6]

[Anonymous], ASCO M ABSTRACTS S

[7] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[8] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].

Antoniou, A ;

Pharoah, PDP ;

Narod, S ;

Risch, HA ;

Eyfjord, JE ;

Hopper, JL ;

Loman, N ;

Olsson, H ;

Johannsson, O ;

Borg, Å ;

Pasini, B ;

Radice, P ;

Manoukian, S ;

Eccles, DM ;

Tang, N ;

Olah, E ;

Anton-Culver, H ;

Warner, E ;

Lubinski, J ;

Gronwald, J ;

Gorski, B ;

Tulinius, H ;

Thorlacius, S ;

Eerola, H ;

Nevanlinna, H ;

Syrjäkoski, K ;

Kallioniemi, OP ;

Thompson, D ;

Evans, C ;

Peto, J ;

Lalloo, F ;

Evans, DG ;

Easton, DF .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130

[9] Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining [J].

Audebert, M ;

Salles, B ;

Calsou, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) :55117-55126

[10] Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner-City Population [J].

Baron, Kaitlin B. ;

Brown, Jennifer R. ;

Heiss, Brian L. ;

Marshall, Joanne ;

Tait, Nancy ;

Tkaczuk, Katherine H. R. ;

Gottlieb, Stephen S. .

JOURNAL OF CARDIAC FAILURE, 2014, 20 (08) :555-559

← 1 2 3 4 5 6 7 8 9 10 →